Fig. 2From: Real-world clinical burden and economic assessment associated with hyperkalaemia in a large integrated healthcare system: a retrospective analysisSignificant predictors of incident HK (sK > 5.5 mmol/L) compared to No-HK (sK ≤ 5.0 mmol/L). ACEi angiotensin-converting enzyme inhibitor; ARB angiotensin-II receptor blocker; CAD coronary artery disease; HK hyperkalaemia; NSAID nonsteroidal anti-inflammatory drug; sK serum potassiumBack to article page